April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Ranibizumab Treatment for Diabetic Macular Edema in a Clinical Routine Setting: 12 Months Results
Author Affiliations & Notes
  • Christian Pruente
    VISTA Klinik, Binningen, Switzerland
  • Katja Hatz
    VISTA Klinik, Binningen, Switzerland
  • Footnotes
    Commercial Relationships  Christian Pruente, Novartis Pharma (F); Katja Hatz, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 563. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Christian Pruente, Katja Hatz; Ranibizumab Treatment for Diabetic Macular Edema in a Clinical Routine Setting: 12 Months Results. Invest. Ophthalmol. Vis. Sci. 2011;52(14):563.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the efficacy of ranibizumab treatment in diabetic macular edema (DME) in a routine clinical setting and correlations of baseline characteristics, Spectral(SD)-OCT and visual acuity outcomes.

Methods: : Data of 30 eyes with visual impairment due to DME with a follow-up of 12 months were analyzed. All eyes were treated following a PRN regimen. Baseline characteristics, OCT results for central retinal thickness (CRT) and volume and best corrected visual acuity (BCVA) results were correlated. Absolute values and a logarithmic transformation of excess CRT were used for calculations. All calculations were performed for 3-, 6-, 9- and 12-months outcomes.

Results: : Mean values at baseline were 473µm for CRT, 8.85 mm3 for macular volume, and 0.46 for LogMAR visual acuity. During the follow-up period of 12 months a mean number of 3.9 ranibizumab injections were given, almost half of these from baseline to month 3 (1.93). CRT significantly (p<0.01) decreased by 68, 73, 85 and 85µm at months 3, 6, 9, and 12. Visual acuity significantly (p<0.01) improved to 0.31, 0.33, 0.29 and 0.30 LogMAR respectively. Greater improvement of BCVA occurred in eyes with shorter duration of macular edema and better baseline visual acuity (≤ 0.4LogMAR). No correlation was found between BCVA change and the absolute change in CRT or macular volume. However a significant correlation (p<0.05) was found between BCVA and the change in CRT based on the logarithmic calculation. No correlation of BCVA could be found with baseline CRT, baseline macular volume, pre-treatments (focal laser coagulation, intravitreal triamcinolone) or the frequency of ranibizumab injections.

Conclusions: : These results suggest that repeated intravitreal injections of ranibizumab can significantly reduce central retinal thickness and improve visual acuity in patients with DME in a clinical routine PRN regimen with a mean of 3.9 injections. Eyes with shorter history of visual impairment and better baseline BCVA seem to show better BCVA improvement. Interesting is the fact that a significant correlation was found between BCVA and excess CRT if calculated in a logarithmic transformation like LogMAR is calculated.

Keywords: diabetic retinopathy • macula/fovea • imaging/image analysis: clinical 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.